D. E. Shaw & Co. Inc. Acquires New Shares in Fate Therapeutics Inc (NASDAQ:FATE)

Share on StockTwits

D. E. Shaw & Co. Inc. acquired a new stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) in the second quarter, Holdings Channel reports. The fund acquired 13,322 shares of the biopharmaceutical company’s stock, valued at approximately $270,000.

Other large investors also recently added to or reduced their stakes in the company. Aperio Group LLC acquired a new position in Fate Therapeutics during the 2nd quarter valued at approximately $79,000. Bank of Montreal Can boosted its position in Fate Therapeutics by 43,680.0% during the 2nd quarter. Bank of Montreal Can now owns 4,378 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 4,368 shares during the period. Cubist Systematic Strategies LLC boosted its position in Fate Therapeutics by 72.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,948 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,086 shares during the period. Meeder Asset Management Inc. boosted its position in Fate Therapeutics by 257.7% during the 2nd quarter. Meeder Asset Management Inc. now owns 10,108 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 7,282 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in Fate Therapeutics by 19.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,263 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 2,763 shares during the period. Institutional investors and hedge funds own 96.59% of the company’s stock.

Shares of FATE stock opened at $14.25 on Friday. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.28. Fate Therapeutics Inc has a 1 year low of $11.00 and a 1 year high of $22.82. The stock has a fifty day moving average of $16.62 and a two-hundred day moving average of $18.29.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.04). Fate Therapeutics had a negative return on equity of 50.05% and a negative net margin of 934.70%. The business had revenue of $2.80 million for the quarter, compared to analyst estimates of $1.09 million. During the same quarter last year, the firm posted ($0.37) EPS. The company’s revenue was up 180.0% compared to the same quarter last year. As a group, research analysts predict that Fate Therapeutics Inc will post -1.43 earnings per share for the current year.

A number of research analysts recently issued reports on the company. BTIG Research assumed coverage on Fate Therapeutics in a research report on Friday, August 9th. They set a “buy” rating and a $27.00 price objective for the company. Zacks Investment Research upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 10th. CIBC assumed coverage on Fate Therapeutics in a research report on Friday, July 12th. They set an “outperform” rating and a $27.00 price objective for the company. Mizuho restated a “buy” rating and set a $27.00 price objective on shares of Fate Therapeutics in a research report on Wednesday, September 4th. Finally, ValuEngine lowered Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have given a buy rating to the company. Fate Therapeutics has an average rating of “Buy” and an average price target of $25.00.

In other Fate Therapeutics news, Director Redmile Group, Llc purchased 857,143 shares of Fate Therapeutics stock in a transaction on Monday, September 16th. The stock was bought at an average price of $17.50 per share, for a total transaction of $15,000,002.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Amir Nashat sold 21,409 shares of the business’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $22.50, for a total value of $481,702.50. The disclosure for this sale can be found here. Insiders have sold a total of 382,641 shares of company stock valued at $8,614,708 in the last quarter. 23.19% of the stock is currently owned by insiders.

Fate Therapeutics Profile

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Featured Story: The four types of profit margin

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics Inc (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.